Canagliflozin Powder Anti-diabetic Drug Medical Grade for Type 2 Diabetes
What is Canagliflozin?
Canagliflozin (trade name Invokana or Sulisent) is a medication used for the treatment of type 2 diabetes. It is of the gliflozin class or subtype 2 sodium-glucose transport (SGLT-2) inhibitors class. This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to sulfonylurea derivatives and insulin.
Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of renal glucose reabsorption (SGLT1 being responsible for the remaining 10%). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine.
Canagliflozin Specification
| Tests |
Specifications |
Results |
| Appearance |
White or off-white powder |
White powder |
| Identification: |
| A. IR(KBr) |
The sample spectrum corresponds
to that of the working standard |
Confirm |
| B. HPLC |
The retention time of the major peak
in the chromatogram of the sample
corresponds to that exhibited by the working standard |
Confirm |
| Single impurity |
Not more than 0.1% |
0.08% |
| Total impurities |
Not more than 1.0% |
0.5% |
| E.e % |
More than 98.5% |
99% |
| Assay (by HPLC) |
Not less than 98.0% and not more than 102.0% w/w |
99.1% |
| Conclusion |
Comply with In-house standard. |
| Storage |
Store protected from light and moisture |
Canagliflozin Medical Use
Canagliflozin is an anti-diabetic drug used to improve glycemic control in people with type 2 diabetes. In extensive clinical trials, canagliflozin produced a consistent dose-dependent decrease in HbA1c levels of 0.77% to 1.16% when administered either as monotherapy, in combination with metformin, in combination with metformin and a sulfonylurea, in combination with metformin and pioglitazone, or in combination with insulin, from initial HbA1c levels of 7.8% to 8.1%.
